Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.40
ACT's Cash-to-Debt is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. ACT: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.42 Max: 32.29
Current: 0.4
0.02
32.29
Equity-to-Asset 0.59
ACT's Equity-to-Asset is ranked lower than
56% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACT: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.63 Max: 0.9
Current: 0.59
0.27
0.9
Piotroski F-Score: 6
Altman Z-Score: 1.30
Beneish M-Score: -2.01
WACC vs ROIC
6.63%
-0.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -12.08
ACT's Operating Margin % is ranked lower than
79% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. ACT: -12.08 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -12.08
-54.9
14.13
Net Margin % 100.04
ACT's Net Margin % is ranked higher than
99% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ACT: 100.04 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.67 Max: 102.76
Current: 100.04
-34.87
102.76
ROE % 18.53
ACT's ROE % is ranked higher than
81% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ACT: 18.53 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 18.53
-11.23
19.24
ROA % 11.06
ACT's ROA % is ranked higher than
80% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. ACT: 11.06 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 11.31
Current: 11.06
-4.32
11.31
ROC (Joel Greenblatt) % -58.17
ACT's ROC (Joel Greenblatt) % is ranked lower than
80% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. ACT: -58.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -112.05  Med: 20.42 Max: 38.44
Current: -58.17
-112.05
38.44
3-Year Revenue Growth Rate 27.40
ACT's 3-Year Revenue Growth Rate is ranked higher than
90% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ACT: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.5 Max: 40.4
Current: 27.4
-16.3
40.4
3-Year EBITDA Growth Rate 41.70
ACT's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. ACT: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 13.1 Max: 67.4
Current: 41.7
-47.7
67.4
3-Year EPS without NRI Growth Rate -1.20
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ACT: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 5.4 Max: 94.3
Current: -1.2
-27.1
94.3
GuruFocus has detected 6 Warning Signs with Allergan PLC $ACT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACT's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA865.786.355 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:MKGAY, OTCPK:ESALF, OTCPK:MTZPY, NYSE:PRGO, OTCPK:SFOSF, OTCPK:HLUKF, OTCPK:IPSEY, OTCPK:APNHF, NYSE:RDY, OTCPK:MDABY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:MNK, NYSE:TARO, OTCPK:GEDSF » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan is one of the largest specialty pharmaceutical manufacturers. Allergan specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Ratios

vs
industry
vs
history
PE Ratio 6.36
ACT's PE Ratio is ranked higher than
95% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. ACT: 6.36 )
Ranked among companies with meaningful PE Ratio only.
ACT' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 24.4 Max: 366.63
Current: 6.36
4.95
366.63
Forward PE Ratio 15.24
ACT's Forward PE Ratio is ranked higher than
63% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. ACT: 15.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.91
ACT's Price-to-Owner-Earnings is ranked higher than
94% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. ACT: 4.91 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.82  Med: 18.51 Max: 1421.16
Current: 4.91
3.82
1421.16
PB Ratio 1.28
ACT's PB Ratio is ranked higher than
82% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ACT: 1.28 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.28
0.87
5.9
PS Ratio 6.38
ACT's PS Ratio is ranked lower than
72% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ACT: 6.38 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 6.38
0.99
17.57
Price-to-Free-Cash-Flow 89.26
ACT's Price-to-Free-Cash-Flow is ranked lower than
87% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. ACT: 89.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 15.66 Max: 90.54
Current: 89.26
6.62
90.54
Price-to-Operating-Cash-Flow 68.06
ACT's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. ACT: 68.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.97  Med: 12.85 Max: 69.03
Current: 68.06
5.97
69.03
EV-to-EBIT -70.01
ACT's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. ACT: -70.01 )
Ranked among companies with meaningful EV-to-EBIT only.
ACT' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 10.95 Max: 104.6
Current: -70.01
-310.4
104.6
EV-to-EBITDA 20.80
ACT's EV-to-EBITDA is ranked lower than
64% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. ACT: 20.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 12.1 Max: 234.9
Current: 20.8
-224.1
234.9
Shiller PE Ratio 52.66
ACT's Shiller PE Ratio is ranked lower than
55% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. ACT: 52.66 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.09  Med: 51.27 Max: 2115.42
Current: 52.66
14.09
2115.42
Current Ratio 2.27
ACT's Current Ratio is ranked lower than
55% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ACT: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.56 Max: 9.8
Current: 2.27
1.03
9.8
Quick Ratio 2.18
ACT's Quick Ratio is ranked higher than
55% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ACT: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.02 Max: 8.82
Current: 2.18
0.8
8.82
Days Inventory 139.08
ACT's Days Inventory is ranked lower than
56% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. ACT: 139.08 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 126.6 Max: 369.82
Current: 139.08
75.66
369.82
Days Sales Outstanding 61.72
ACT's Days Sales Outstanding is ranked higher than
62% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ACT: 61.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 61.72
39.05
197.04
Days Payable 37.39
ACT's Days Payable is ranked lower than
80% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. ACT: 37.39 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.03  Med: 69.22 Max: 109.48
Current: 37.39
28.03
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.10
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ACT: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -29.1
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.25
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACT: 1.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.21 Max: 4.68
Current: 1.25
0.6
4.68
Price-to-Median-PS-Value 3.47
ACT's Price-to-Median-PS-Value is ranked lower than
92% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ACT: 3.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 2.32 Max: 5.54
Current: 3.47
0.67
5.54
Earnings Yield (Greenblatt) % -1.43
ACT's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ACT: -1.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 6 Max: 12.3
Current: -1.43
1
12.3
Forward Rate of Return (Yacktman) % 11.00
ACT's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. ACT: 11.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.2  Med: 7.7 Max: 16.1
Current: 11
-0.2
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition Apr 28 2017 
Weitz Value Fund Comments on Allergan Apr 27 2017 
Jerome Dodson Comments on Allergan Apr 26 2017 
Jerome Dodson's 1st Quarter Parnassus Fund Commentary Apr 26 2017 
PBF Energy Set to Join S&P MidCap 400; Apollo Commercial Real Estate Finance and Waddell & Reed Fina Apr 25 2017 
Has Seth Klarman Sold Cheniere Energy Entirely? Apr 25 2017 
Jerome Dodson Keeps Buying McKesson, Axalta, Pentair Apr 25 2017 
Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimu Apr 25 2017 
Charlie Munger: Loading Up on Leverage Apr 21 2017 
Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Apr 21 2017 

More From Other Websites
Bill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million Mar 29 2017
Risk-Reward With Teva Pharmaceutical Mar 27 2017
Court allows Allergan shareholders to go after Ackman, Valeant as a class Mar 16 2017
[$$] William Ackman’s Pershing Square Sold Stake in Valeant Mar 13 2017
Allergan plc Question if a Feminist Can Love Fillers? Mar 09 2017
Billionaires Love These 3 Healthcare Stocks Mar 05 2017
The Zacks Analyst Blog Highlights: IBM, Allergan, Chubb, DISH Network and HP Feb 27 2017
Facing Criticism, Drug Makers Keep Lid On Price Increases Feb 27 2017
Allergan CEO Pushes for Trump to Lead Drug Price Discussions Feb 22 2017
Allergan CEO: Gov’t taking over drug pricing is last thing we need Feb 22 2017
Allergan CEO: I don’t know if we’d relocate after tax reform Feb 22 2017
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
5 Ways Allergan Can Keep Up Momentum Feb 15 2017
Billionaire Dan Loeb’s Biggest Q4 Moves Include Bank-Buying Spree, Selling Allergan (AGN) Feb 15 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13% Feb 13 2017
Why Chemours, Zeltiq Aesthetics, and Vale Jumped Today Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 bln Feb 13 2017
Allergan To Buy Fat-Freezing Zeltiq For $2.5 Bil; Zeltiq Hits Record High Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)